Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Cybin Inc.

< Previous 1 2 3 4 5 6 7 Next >
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Present at the TD Cowen 44th Annual Health Care Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Reports Third Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Reports Second Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional Shareholders
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces up to US$64 Million Offering of Units
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate at the 2023 Milken Institute Future of Health Summit
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
From Cybin Inc.
Via Business Wire
Tickers CYBN DMTTF TSX-V:DMT
Small Pharma Obtains Final Order Approving Arrangement
From Cybin Inc.
Via Business Wire
Tickers CYBN DMTTF TSX-V:DMT
Cybin Announces Results of Annual and Special Meeting of Shareholders
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summit
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial
From Cybin Inc.
Via Business Wire
Tickers CYBN
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.